Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): A population pharmacokinetic/pharmacodynamic (PKPD) approach

被引：1
|
作者：
Houk, B. E.
Bello, C. L.
Michaelson, M. D.
Bukowski, R. M.
Redman, B. G.
Hudes, G. R.
Wilding, G.
Motzer, R. J.
机构：
[1] Pfizer Global Res & Dev, La Jolla, CA USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44106 USA
[4] Univ Michigan, Ann Arbor, MI 48109 USA
[5] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[6] Univ Wisconsin, Madison, WI USA
[7] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5027
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A population pharmacokinetic/pharmacodynamic (PK/PD) analysis of exposure-response for sunitinib in metastatic renal cell carcinoma (mRCC)
    Houk, B. E.
    Bello, C. L.
    Michaelson, M. D.
    Bukowski, R. M.
    Redman, B.
    Hudes, G. R.
    Wilding, G.
    Motzer, R. J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 300 - 300
  • [2] Gut microbiome composition and response to sunitinib in metastatic renal cell carcinoma (mRCC).
    Gong, Jun
    Dizman, Nazli
    Poroyko, Valeriy
    Won, Haejung
    Bergerot, Cristiane Decat
    Bergerot, Paulo Gustavo
    Maia, Manuel C.
    Hsu, Joann
    Frankel, Paul Henry
    Jones, Jeremy
    Salgia, Ravi
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [3] Long-term response to sunitinib treatment in metastatic renal cell carcinoma (mRCC).
    Tannir, Nizar M.
    Figlin, Robert A.
    Gore, Martin Eric
    Michaelson, Dror
    Motzer, Robert J.
    Porta, Camillo
    Rini, Brian I.
    Hoang, Caroline J.
    Lin, Xun
    Escudier, Bernard
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [4] WBC changes as a pharmacodynamic marker of outcome in metastatic renal cell carcinoma (mRCC) patients (Pts) receiving sunitinib
    George, S.
    Richmond, A.
    Elson, P.
    Jin, T.
    Wood, L.
    Garcia, J. A.
    Rini, B. I.
    Finke, J.
    Bukowski, R. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] Sunitinib safety and tolerability in patients with metastatic renal cell carcinoma (MRCC)
    Ferrari, A.
    Sabbatini, R.
    Maur, M.
    Giovannelli, S.
    Jovic, G.
    Conte, P.
    ANNALS OF ONCOLOGY, 2006, 17 : XI83 - XI83
  • [6] Exposure-response relationships in patients with metastatic renal cell carcinoma receiving sunitinib: maintaining optimum efficacy in clinical practice
    Ravaud, Alain
    Bello, Carlo L.
    ANTI-CANCER DRUGS, 2011, 22 (05) : 377 - 383
  • [7] Looking for predictive biomarkers for sunitinib in metastatic renal clear cell carcinoma (mRCC)
    Maroto, P.
    Esteban, E.
    Méndez-Vidal, M. J.
    Fernandez-Parra, E. M.
    Leon, L.
    Perez-Valderrama, B.
    Domenech, M.
    Calderero, V.
    Perez-Gracia, J. L.
    Algaba, F.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S676 - S676
  • [8] SAFETY PROFILE OF SUNITINIB AND SORAFENIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
    Massari, Francesco
    Sperandi, Francesca
    Cricca, Antonia
    Melotti, Barbara
    Martoni, Andrea Angelo
    ANNALS OF ONCOLOGY, 2009, 20
  • [9] CARDIOTOXICITY IN METASTATIC RENAL CELL CARCINOMA (mRCC) PATIENTS TREATED WITH SUNITINIB (SU)
    Ballatore, Valentina
    Prati, Veronica
    Ruatta, Fiorella
    Galizia, Danilo
    Grignani, Giovanni
    Aglietta, Massimo
    Ortega, Cinzia
    ANTICANCER RESEARCH, 2012, 32 (05) : 1876 - 1877
  • [10] Pharmacokinetics (PK) and efficacy of sunitinib in patients with metastatic renal cell carcinoma (mRCC).
    Houk, B. E.
    Amantea, M.
    Motzer, R. J.
    Michaelson, M. D.
    Rini, B. I.
    George, D. J.
    Redman, B. G.
    Hudes, G. R.
    Poland, B.
    Bello, C. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 224S - 224S
12345